Motor symptoms are not the only effects of Parkinson's disease; many affected individuals experience issues with sleep, among other symptoms. In fact, a panel of experts recently came together to…
In a recent press release, clinical-stage biopharmaceutical company Abeona Therapeutics Inc. ("Abeona") shared that the company had a successful Type B meeting with the FDA. During the meeting, Abeona explained…
At the very start of the new year, researchers out of the Washington University in St. Louis shared some exciting medical research: the discovery of two gene variants, associated with…
Parkinson’s News Today recently featured an upbeat article describing the progress that researchers have made in developing a method of measuring alpha-synuclein’s (AS) progression that cuts discovery time in…
Kuur Therapeutics has recently released interim data on their CAR-NKT cell therapy platform, which was created for the treatment of hematological and solid malignancies. This data comes from two phase…
In a press release shared at UEG week Virtual 2020, researchers shared a new study conducted over nearly two decades which found that people who’d had asthma or an allergy…
Each year, January 24 marks International Alagille Syndrome Awareness Day. During this day, organizations across the globe raise awareness around Alagille Syndrome (ALGS), from offering educational resources to allowing patients…
According to Medical XPress, researchers out of the Queen Mary University of London have been making strides in the field of medical research, particularly around pancreatic cancer. After identifying a…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
